Memantina Tarbis

Memantine, the active ingredient in Memantina Tarbis, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed to treat moderate to severe Alzheimer’s disease in adult patients. The formulation is designed for systemic absorption and is marketed within the European Union.

GNH USA supplies Memantina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice (GDP) standards, ensuring product quality, traceability, and regulatory compliance across global supply chains.

Memantine acts on the glutamatergic pathway and is indicated for the following Alzheimer’s disease conditions.

Alzheimer’s disease (moderate to severe): improves cognitive function and daily living activities. Alzheimer’s disease (any stage): may help maintain cognition and slow functional decline. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression.

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe rash (e.g., Stevens‑Johnson syndrome) - Psychosis or suicidal thoughts

When prescribing memantine, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: assess kidney function and adjust dose if necessary. Hepatic impairment: monitor liver enzymes and use with caution. History of seizures: evaluate risk and monitor for seizure activity. Elderly patients: observe for increased sensitivity to dizziness and confusion. Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. Pregnancy: safety not established; use only if potential benefit justifies potential risk. Store at ambient temperature: keep in original packaging, protect from moisture.

Memantine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxic effects. - Ketamine: additive NMDA blockade can enhance central nervous system depression. - Other NMDA antagonists: concurrent use may lead to excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - Diuretics: can potentiate hypotensive effects. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation.